Last reviewed · How we verify
RAS 2410
RAS 2410 is a selective inhibitor of the RAS pathway.
RAS 2410 is a selective inhibitor of the RAS pathway. Used for Non-small cell lung cancer, Colorectal cancer.
At a glance
| Generic name | RAS 2410 |
|---|---|
| Also known as | No specific restrictions |
| Sponsor | Nan Chen,MD |
| Drug class | RAS pathway inhibitor |
| Target | KRAS |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
RAS 2410 works by blocking the activity of the RAS protein, which is involved in cell growth and division. This can help to slow or stop the growth of cancer cells. By inhibiting the RAS pathway, RAS 2410 may help to reduce the size of tumors and slow disease progression.
Approved indications
- Non-small cell lung cancer
- Colorectal cancer
Common side effects
- Diarrhea
- Fatigue
- Nausea
Key clinical trials
- Rituximab and RASi in Patients with IgAN (PHASE4)
- Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS) (PHASE2)
- A Phase 1, Open-label Study of the Absorption, Metabolism, Excretion of [14C]-Resminostat (PHASE1)
- Resminostat (YHI-1001) in Combination With Sorafenib in Asian Patients With Advanced Hepatocellular Carcinoma (HCC) (PHASE1, PHASE2)
- 4SC-201 (Resminostat) in Advanced Colorectal Carcinoma (PHASE1, PHASE2)
- Resminostat (4SC-201) in Relapsed or Refractory Hodgkin's Lymphoma (PHASE2)
- 4SC-201 (Resminostat) and Sorafenib in Advanced Hepatocellular Carcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RAS 2410 CI brief — competitive landscape report
- RAS 2410 updates RSS · CI watch RSS
- Nan Chen,MD portfolio CI